Seattle Genetics
MSD partners up with Seattle Genetics in two oncology development deals potentially worth over $4bn
September 15, 2020Manufacturing and Production, Sales and Marketing MSD, Seattle Genetics, deal, pharma
MSD has signed two new oncology-based deals with Seattle Genetics which together could be worth up to around $4.4 billion. …
FDA approves Seattle Genetics and Astellas Pharma’s bladder cancer drug
December 19, 2019Business Services Astellas Pharma, Cancer, Padcev, Seattle Genetics, bladder cancer
The FDA has granted accelerated approval for Seattle Genetics and Astellas Pharma’s bladder cancer drug Padcev (enfortumab vedotin-ejfv). The drug’s …
Immunomedics’ whirlwind in the C-suite continues
April 10, 2018Manufacturing and Production, Medical Communications AstraZeneca, Immunomedics, Seattle Genetics, biotech, drugs, pharma, pharmaceutical
Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, …
Seattle Genetics gain breakthrough therapy designation
March 26, 2018Manufacturing and Production, Sales and Marketing Astellas, Seattle Genetics, biotech, drugs, pharma, pharmaceutical
Seattle Genetics and Astellas have confirmed that the drug candidate they are co-developing, enfortumab, has been given FDA breakthrough therapy …
Seattle in $614m move for Cascadian Therapeutics
January 31, 2018Sales and Marketing Cascadian Theapeutics, HER2, Seattle Genetics, biotech, drugs, pharma, pharmaceutical
Things don’t always go quite according to plan in the biotech world – something both Seattle Genetics and Cascadian Therapeutics …
Board battle scuppers Seattle Genetics’ $2 billion licensing deal
May 8, 2017Sales and Marketing Immunomedics, Seattle Genetics, venBio
In another example of the influence that activist investors can have on the direction of a business, the potentially $2 …
Seattle Genetics’ prospective $2 billion licensing deal not without controversy
February 13, 2017Sales and Marketing Immunomedics, Seattle Genetics, enVio
Immunomedics announced on 10 February that it had entered a licensing agreement with Seattle Genetics for its leading experimental cancer …
Four die in Seattle Genetics’ drug trial
January 3, 2017Manufacturing and Production, Medical Communications, Sales and Marketing Seattle Genetics, patient deaths, trial hold
Seattle Genetics released that the FDA had placed a hold had been placed on clinical trials involving its experimental cancer …
Phase III success for Takeda in lymphoma drug
August 1, 2016Manufacturing and Production, Research and Development Adcetris, Seattle Genetics, Takeda, lymphoma
Takeda Oncology and Seattle Generic have announced new Phase III data for trial drug, Adcetris (brentuximab vedotin), in patients with …
Blood cancer drug Adcetris approved by FDA
August 24, 2011Sales and Marketing Adcetris, Cancer, Seattle Genetics, lymphoma
The FDA has approved Seattle Genetics’ blood cancer drug Adcetris for two forms of lymphoma. Adcetris (brentuximab vedotin) can now …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
